This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.



JOYCE P. GRIFFIN-SOBEL, RN, PHD, AOCN[®], APRN-BC Editor

Reader Comments on Antithymocyte Globulin Use for Aplastic Anemia

I wanted to thank you for your comprehensive article "Management of Patients Receiving Antithymocyte Globulin for Aplastic Anemia and Myelodysplastic Syndrome" in the August issue of the *Clinical Journal of Oncology Nursing* (Vol. 8, pp. 377–382). We have been using antithymocyte globulin (ATG) at the Fred Hutchinson Cancer Research Center in Seattle, WA, for the past two decades as pretransplant conditioning for aplastic anemia (AA) and in various protocols for the treatment of graft-versus-host disease.

I also wanted to mention that when adhering to the caveats you describe, ATG can be administered safely in the outpatient setting. Hours of operation tend to be more of a limiting factor, and we are careful to schedule patients first thing in the morning. We have found reactions to be less common than other agents administered in our clinic (e.g., rituximab, paclitaxel, carboplatin), although admittedly we administer more of those agents so a direct comparison cannot be made. As you clearly point out, emergency equipment and properly trained personnel need to be immediately available, and staff education is extremely important as well.

> Seth Eisenberg, RN, OCN® Infusion Practice Coordinator Seattle Cancer Care Alliance Seattle, WA

The Authors Respond

We appreciate Mr. Eisenberg's thoughtful comment and would like to offer a response regarding the standards of care for patients receiving ATG in the outpatient setting. We agree that ATG is commonly used as part of the preparative regimen in allogeneic hematopoietic stem cell transplantation (HSCT) for various diseases (Simpson, 2003; Storb et al., 2001) as well as graft-versus-host disease resulting from HSCT (Bacigalupo et al., 2001; Remberger, Aschan, Barkholt, Tollemar, & Ringden, 2001). The dose and schedule for both of these indications are not standardized, however, and often is determined based on institutional protocols.

It is important to reiterate that the indication for administration of high-dose "Atgam® [Pfizer Inc., New York, NY] (40 mg/kg per day) and Thymoglobulin® [Genzyme Corporation, Cambridge, MA] (3.5 mg/kg per day) in patients with AA and myelodysplastic syndrome" is outside the setting of HSCT. Although institutional protocols guide the delivery of any complex therapy, we would like to advocate for interdisciplinary collaboration and thorough discussion prior to the administration of ATG in any care setting. This decision making should be conducted in the context of the potential infusional toxicities based on patients' risk evaluation and their overall care needs. Additionally, staff competency and institution support, such as availability of a physician or nurse practitioner, and emergency medications and supplies must factor in the decision. Moreover, the recommendations in our article can be used to guide the provision of care to patients receiving ATG for any indication, and we advocate thoughtful interdisciplinary planning prior to its administration.

> Margaret F. Bevans, RN, MS, AOCN® Clinical Nurse Specialist Clinical Center National Institutes of Health Bethesda, MD

Reem A. Shalabi, PharmD, BCOP Clinical Pharmacy Specialist Blood and Marrow Transplantation National Institutes of Health Bethesda, MD

References

- Bacigalupo, A., Oneto, R., Lamparelli, T., Gualandi, F., Bregante, S., Raiola, A.M., et al. (2001). Graft versus host disease. Pre-emptive therapy of acute graft versus host disease: A pilot study with antithymocyte globulin (ATG). *Bone Marrow Transplantation, 28,* 1093–1096.
- Remberger, M., Aschan, J., Barkholt, L., Tollemar, J., & Ringden, O. (2001). Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. *Clinical Transplantation*, 15, 147–153.

- Simpson, D.R. (2003). T-cell depleting antibodies. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 17, 147–154.
- Storb, R., Blume, K.G., O'Donnell, M.R., Chauncy, T., Forman, S.J., Deeg, J., et al. (2001). Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers. *Biology of Blood and Marrow Transplant*, 7, 39–44.

ONS Publishing Division Policy Regarding "Letters to the Editor"

Selection of letters to be published in "Letters to the Editor" is the decision of the editors of the Clinical Journal of Oncology Nursing (CJON) or ONS News. For acceptance, letters must be signed. They can appear anonymously if requested by the author. All letters are subject to editing. Letters that question, criticize, or respond to a previously published CJON article will be sent to the author of that article for a reply. This type of collegial exchange is encouraged. Letters that question, criticize, or respond to an Oncology Nursing Society (ONS) policy, product, or activity will appear in ONS News and automatically will be sent to the ONS Board of Directors for a reply. Designation of a letter to CJON or ONS News shall be agreed upon by the CJON and ONS News editors.

Letters should be mailed to Joyce P. Griffin-Sobel, RN, PhD, AOCN[®], APRN-BC, Hunter-Bellevue School of Nursing, 749 West End Avenue, Apt. 9B, New York, NY, 10025 or emailed to CJONeditor@jsobel.com.

Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.

Digital Object Identifier: 10.1188/04.CJON.583